At Medicilon, we are dedicated to help our clients develop their research and discovery programs from a burst of ideas all the way to the Investigational New Drug (IND) filing phase. Our service span across medicinal chemistry, biology, API synthesis, CMC and preclinical studies. Medicilon（stock code : 688202.SH）is fully accredited by the International Laboratory Animal Assessment and Accreditation (AAALAC) and in compliance with the US FDA’s Good Laboratory Practice (GLP). The standard of laboratories is certified by the National Medical Products Administration(NMPA) for GLP compliance in China. Experimental reports present by Medicilon are valid for China and USA dual filing to facilitate the evaluation of the safety and marketing of life-changing compounds for our clients.
Over 16 Years’ Experience on R&D
1200+ Employees Delivering Professional Services Globally
More Than 500 Active Clients and Partners Worldwide
300000 sq. ft. Lab and Animal Facilities Space
Services
-
Integrated Projects
Medicilon also offers other services including but not limited to evaluation of compound medicines, chemical drugs,Read more
-
Drug Safety Evaluation
The preclinical services that Medicilon offers focus on preclinical pharmacokinetic and safety evaluation for foreign andRead more
-
Bioanalytical Services
Medicilon offers a full range of Bioanalytical Services supporting various aspects of the drug discovery andRead more
-
Pharmacokinetic Services
Medicilon completes at least 8 IND packages and more than 1,000 individual pharmacokinetic studies every year.Read more
-
Pharmacology Services
Medicilon’s Pharmacology department functions in accordance with the needs of our customers for a variety ofRead more
-
Biology Services
The Biology department of Medicilon has an extensive experience in molecular biology, cell biology, in vitroRead more
-
Drug Formulation
We have the professional formulation technical platform and the most experienced team, which could offer fullyRead more
-
Chemistry Services
Our chemistry platform is designed and developed to address the challenges of comtemporary and complicated drugRead more
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH). IPAH is a progressive disease that affects the precapillary pulmonary vasculature. IPAH is a rare and fatal disease which has a high mortality rate.